GBL

Affidea Group appoints Frans van Houten, Former CEO of Philips, as a new Supervisory Board member

Retrieved on: 
Friday, January 19, 2024

Frans van Houten stated: "Affidea stands as a fast-growth European healthcare champion renowned for its innovative spirit—a spirit I am thrilled to support.

Key Points: 
  • Frans van Houten stated: "Affidea stands as a fast-growth European healthcare champion renowned for its innovative spirit—a spirit I am thrilled to support.
  • Michal Chalaczkiewicz, Chairman of Affidea's Supervisory Board and Investment Partner at GBL, added: "We are delighted to welcome Frans van Houten to Affidea's Supervisory Board, joining the other distinguished members.
  • Guy Blomfield, CEO of Affidea Group and Chairman of the Management Board, stated: "We warmly welcome Frans to our Supervisory Board.
  • Frans van Houten joins the Supervisory Board alongside Affidea management, GBL representatives and Dimitris Moulavasilis who joined as a non-executive Director in 2022.

Affidea Group appoints Frans van Houten, Former CEO of Philips, as a new Supervisory Board member

Retrieved on: 
Friday, January 19, 2024

Frans van Houten stated: "Affidea stands as a fast-growth European healthcare champion renowned for its innovative spirit—a spirit I am thrilled to support.

Key Points: 
  • Frans van Houten stated: "Affidea stands as a fast-growth European healthcare champion renowned for its innovative spirit—a spirit I am thrilled to support.
  • Michal Chalaczkiewicz, Chairman of Affidea's Supervisory Board and Investment Partner at GBL, added: "We are delighted to welcome Frans van Houten to Affidea's Supervisory Board, joining the other distinguished members.
  • Guy Blomfield, CEO of Affidea Group and Chairman of the Management Board, stated: "We warmly welcome Frans to our Supervisory Board.
  • Frans van Houten joins the Supervisory Board alongside Affidea management, GBL representatives and Dimitris Moulavasilis who joined as a non-executive Director in 2022.

Sathgen Therapeutics completes dosing of the first two cohorts of healthy volunteers with MSP008-22, a novel anti-viral drug

Retrieved on: 
Thursday, August 10, 2023

MUMBAI, India, Aug. 10, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of the leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), announced that they completed the dosing of the first two healthy volunteer cohorts in a Phase 1 clinical trial for MSP008-22, their new chemical entity (NCE). The clinical trial program is managed by Clinexel Life Sciences, a renowned clinical research organization in the pharmaceutical sector.

Key Points: 
  • Sathgen is a clinical-stage novel therapeutics venture focused on bringing therapies for difficult-to-treat diseases like viral infections.
  • Their lead molecule, MSP008-22, has widespread anti-viral potential due to its ability to inhibit both viral entry and replication.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University; Co-Founder, Sathgen Therapeutics, stated, "Viral diseases with the ability to lead to pandemics have limited treatment options.
  • Mr. Samir Somaiya, Chairman and MD, GBL; Co-Founder, Sathgen Therapeutics, highlighted the company's commitment to research and its goal in discovering therapies for difficult-to-treat diseases.

Prodrugs: pills your body converts into an illicit drug can evade detection, but we don't know how big the problem is

Retrieved on: 
Monday, July 24, 2023

Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.

Key Points: 
  • Prodrugs are substances that can only cause an effect after being broken down by enzymes in the digestive system or other chemical reactions in the body.
  • Most illicit drugs work by interacting with specific brain cell receptors, stimulating or blocking the release of chemicals called neurotransmitters.
  • They last for a short time before being transformed into inactive or less active chemicals, which are then eliminated from the body, usually in urine.
  • For prodrugs, however, a small part of the molecule needs to be removed or substituted before it can act on those receptors.

Hard to detect

    • A major problem with prodrugs is they are difficult to detect.
    • Police forces need reference samples to compare the drug with, or advanced equipment to discover its molecular structure.
    • It also explains why many have only appeared in police reports in the past decade.
    • For biological samples (such as blood, urine or saliva), there is another difficulty.

Sathgen Therapeutics announces dosing of the first patient cohort with MSP008-22, a novel anti-cancer drug

Retrieved on: 
Thursday, July 20, 2023

MUMBAI, India, July 20, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of a leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), has announced the completion of the first cohort in a Phase 1 clinical trial for their first-in-class New Chemical Entity, MSP008-22. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the health sector.

Key Points: 
  • Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle.
  • MSP008-22 effectively targets treatment-resistant cancer cells in preclinical models, and demonstrates an excellent safety profile with no serious adverse events in the first patient cohort.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University, and Scientific Co-Founder, Sathgen Therapeutics, stated, "TNBC is responsible for 30% of breast cancer-related deaths.
  • With over 15 anti-cancer candidates in the pipeline, Sathgen Therapeutics remains committed to advancing cancer therapeutics.

Sathgen Therapeutics announces dosing of the first patient cohort with MSP008-22, a novel anti-cancer drug

Retrieved on: 
Thursday, July 20, 2023

MUMBAI, India, July 20, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of a leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), has announced the completion of the first cohort in a Phase 1 clinical trial for their first-in-class New Chemical Entity, MSP008-22. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the health sector.

Key Points: 
  • Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle.
  • MSP008-22 effectively targets treatment-resistant cancer cells in preclinical models, and demonstrates an excellent safety profile with no serious adverse events in the first patient cohort.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University, and Scientific Co-Founder, Sathgen Therapeutics, stated, "TNBC is responsible for 30% of breast cancer-related deaths.
  • With over 15 anti-cancer candidates in the pipeline, Sathgen Therapeutics remains committed to advancing cancer therapeutics.

Concentrix to Combine with Webhelp, Creating a Diversified Global CX Leader, Well-Positioned for Growth

Retrieved on: 
Wednesday, March 29, 2023

With our combined strengths, we will be uniquely positioned to redefine the industry and design, build and run the future of CX,” said Chris Caldwell.

Key Points: 
  • With our combined strengths, we will be uniquely positioned to redefine the industry and design, build and run the future of CX,” said Chris Caldwell.
  • Webhelp will add approximately 1,000 clients to Concentrix, including 25+ Fortune Global 500 and 200+ new economy clients.
  • The combined company will have approximately 2,000 clients, including 155 Fortune Global 500 clients and 320 new economy clients.
  • Additionally, the combination is also expected to accelerate Concentrix Catalyst’s global reach by adding Webhelp’s engineering talent in Europe and Latin America.

Wipro Announces a New Global Business Line Model to Deepen Alignment with Client Priorities

Retrieved on: 
Monday, February 27, 2023

Under the new model, Wipro will now deliver capabilities to clients through four GBLs organized around cloud, enterprise technology and business transformation, engineering, and consulting.

Key Points: 
  • Under the new model, Wipro will now deliver capabilities to clients through four GBLs organized around cloud, enterprise technology and business transformation, engineering, and consulting.
  • Cloud native applications, cloud architecture, apps modernization, cloud strategy and migration, as well as cloud infrastructure, will all fall under this business line.
  • Jo Debecker, who currently leads Wipro’s Cloud Infrastructure Services, will lead this business, and assume the title of Global Head of Wipro FullStride Cloud.
  • Wipro Engineering Edge, which was launched in 2022 to advance Wipro’s position as a global engineering services leader, will become a standalone business line.

Green Bioactives engages biomanufacturing expert John Stevenson to lead production scale-up

Retrieved on: 
Tuesday, February 21, 2023

John will support GBL in scaling production of its plant-cell based biomanufacturing platform as the company initiates its expansion plans and launch of new products.

Key Points: 
  • John will support GBL in scaling production of its plant-cell based biomanufacturing platform as the company initiates its expansion plans and launch of new products.
  • John has over 35 years engineering and biomanufacturing experience and has a proven track record of delivering complex projects across public, private and start-up companies.
  • David McElroy, CEO of Green Bioactives, commented: “I am thrilled to welcome John to the team at Green Bioactives.
  • John has proven experience in scaling biotechnologies from the lab through to commercialisation and his operational expertise will be invaluable to Green Bioactives at this exciting time for everyone at the company.”
    John Stevenson added: “I am delighted to support Green Bioactives.

Outlook on the Game-Based Learning Global Market to 2027: Players Include Breakaway, Centrical, Duolingo, Edapp and Filament Games

Retrieved on: 
Thursday, February 16, 2023

Delayed change is a positive thing, as it helps to prevent the hazards of implementing educational fads before they have been thoroughly evaluated.

Key Points: 
  • Delayed change is a positive thing, as it helps to prevent the hazards of implementing educational fads before they have been thoroughly evaluated.
  • Therefore, it results in a system that is slow to adapt to the world of technology, which is changing at a rapid rate.
  • New advances such as digital learning and subscription-based learning in learning styles have evolved with various functionalities that are significantly enriching the learning experience, as technology has continued to change the field of education.
  • These learning strategies have improved the accessibility of educational institutions and their resources through e-Learning platforms.